Bridging Therapy: How to Safely Switch Between Blood Thinners

1

December

Switching between blood thinners isn’t just a matter of stopping one pill and starting another. Get it wrong, and you could face a stroke, a pulmonary embolism, or dangerous bleeding. This is where bridging therapy comes in - but only for a small group of people. For most, it’s unnecessary, risky, and outdated.

What Is Bridging Therapy, Really?

Bridging therapy means using a fast-acting injectable blood thinner - like low molecular weight heparin (LMWH) or unfractionated heparin - while temporarily stopping a longer-acting one like warfarin. The goal? To keep your blood from clotting during surgery or a procedure when your regular medication is paused.

But here’s the catch: you don’t need it unless you’re at very high risk for clots. Most people on blood thinners today - especially those taking DOACs like apixaban or rivaroxaban - don’t need bridging at all. The idea used to be routine. Now, it’s reserved for just a few.

Who Actually Needs Bridging?

Not everyone on warfarin needs a bridge. In fact, only about 10-15% of patients do, based on 2021 guidelines. You might need it if you have:

  • A mechanical heart valve in the mitral position
  • A blood clot in your leg or lung within the last 3 months
  • A CHA₂DS₂-VASc score of 5 or higher (for atrial fibrillation) AND a history of stroke or TIA
If you have atrial fibrillation but no prior stroke, no mechanical valve, and no recent clot - you’re not in the high-risk group. Bridging won’t help you. It’ll only raise your bleeding risk.

The BRIDGE trial in 2015 changed everything. Researchers gave half of patients with atrial fibrillation a heparin bridge during surgery. The other half didn’t. The results? No difference in strokes. But the bridged group had more major bleeding - 2.3% vs. 1.0%. That’s more than double the risk for no benefit.

Why DOACs Changed the Game

Direct oral anticoagulants (DOACs) like Eliquis, Xarelto, and Pradaxa are now the go-to for most new patients. Why? They don’t need bridging.

Unlike warfarin, which takes days to clear from your body, DOACs leave your system in hours. Apixaban? Half-life is 12 hours. Rivaroxaban? 7-11 hours. Dabigatran? Around 14 hours. That means you can stop them 24-48 hours before surgery, and your blood’s natural clotting ability returns fast enough to make bridging pointless.

The 2018 AC Forum guidelines say it clearly: “Bridging is not necessary in DOAC patients due to the rapid onset and offset.” No injections. No daily shots. No extra cost. No increased bleeding risk.

In 2023, 75% of new anticoagulant prescriptions were for DOACs. That’s not a trend - it’s the new standard. If you’re still on warfarin, ask why.

Medical chart comparing high-risk patient receiving injection vs. low-risk patient pausing pill.

How Bridging Works - If You Really Need It

If your doctor says you’re high-risk and need a bridge, here’s what it looks like:

  1. Stop warfarin 5-6 days before your procedure. This lets your INR drop below 2.0.
  2. Start therapeutic-dose LMWH (like enoxaparin) 3 days before surgery. Usually 1 mg/kg twice daily.
  3. Stop the LMWH 24 hours before the procedure. For high-bleeding-risk surgeries, sometimes 36-48 hours.
  4. After surgery, restart LMWH 24-48 hours later - only if there’s no bleeding.
  5. Restart warfarin the same day you restart LMWH, but at 15-20% higher than your old dose.
  6. Check your INR in 3-4 days. Adjust as needed.
This isn’t DIY. It requires coordination between your doctor, surgeon, and pharmacist. Miss a dose. Delay a shot. Get the timing wrong. You’re at risk.

The Hidden Costs - Beyond Money

Bridging isn’t just risky. It’s expensive and burdensome.

A 7-day course of LMWH in the U.S. costs $300-$500. In New Zealand, it’s covered under public health, but you still need to inject yourself twice a day. That’s 14 shots. For many older patients, that’s painful, intimidating, or impossible without help.

Studies show 15-20% of patients miss at least one injection. That’s not just non-adherence - it’s a safety gap. One missed dose can mean a clot forms while you’re waiting for the next shot.

And then there’s the anxiety. You’re stuck with needles, blood tests, and uncertainty. Meanwhile, DOAC patients just pause their pill, go in for surgery, and restart it the next day.

What About Restarting After Surgery?

Restarting your blood thinner after surgery is just as important as stopping it safely.

For warfarin: Restart at 15-20% higher than your pre-op dose. Check INR in 3-4 days. Don’t wait until you’re home. Do it while you’re still in the hospital if possible.

For LMWH: Restart 24-48 hours after surgery, depending on bleeding risk. Low-risk procedures (like colonoscopy)? 24 hours. High-risk (like brain or spinal surgery)? Wait 48-72 hours.

For DOACs: Restart 24 hours after low-bleeding-risk procedures. Wait 48-72 hours after major surgery. Your kidney function matters - if it’s poor, delay longer.

Never restart both warfarin and LMWH at the same time without medical supervision. Over-anticoagulation can cause internal bleeding.

Elderly person facing wall of syringes, with clean path to pill and rising sun.

Why Doctors Still Overuse Bridging

Despite the evidence, many doctors still bridge too often. Why?

Old habits. Fear of lawsuits. Lack of updated training. Some still think, “Better safe than sorry.” But the data says otherwise.

The ACC’s “Primum Non Nocere” principle - “first, do no harm” - should guide every decision. Bridging harms more than it helps for most people.

A 2020 study found that 60% of patients who got bridged didn’t meet high-risk criteria. That’s overtreating. That’s unnecessary risk.

Ask your doctor: “Am I in the 10-15% who need this? Or am I being bridged out of habit?”

What You Should Do Right Now

If you’re on a blood thinner and have a procedure coming up:

  • Know which one you’re on - warfarin or a DOAC?
  • Know your CHA₂DS₂-VASc and HAS-BLED scores. Ask your doctor for them.
  • Ask: “Do I really need bridging? What’s the evidence for me?”
  • If you’re on a DOAC, expect to hear: “No bridge needed.”
  • If you’re on warfarin and have no mechanical valve or recent clot, ask why you’re being bridged.
  • Make sure your surgeon and pharmacist are on the same page. Write it down. Confirm it.
Don’t assume. Don’t accept. Ask.

The Future of Blood Thinners

Bridging therapy is fading. It’s not going away completely - but it’s becoming a relic for a shrinking group.

DOACs are cheaper, safer, and easier. Newer anticoagulants are in development with even faster clearance times. In 5 years, bridging may only be mentioned in medical textbooks.

For now, the message is clear: If you’re not at very high risk for clots, don’t let anyone talk you into needles, shots, and extra danger. Your body doesn’t need it. The science doesn’t support it. And your safety does.

Do I need bridging therapy if I’m on Eliquis or Xarelto?

No. Direct oral anticoagulants (DOACs) like Eliquis and Xarelto leave your system quickly - within hours. You can stop them 24-48 hours before surgery and restart them the same day or next day, depending on bleeding risk. Bridging with injections adds no benefit and increases bleeding risk. This is the standard for 75% of new patients today.

What if I’m on warfarin and need a procedure?

Stop warfarin 5-6 days before surgery. Only start bridging with LMWH if you have a mechanical mitral valve, a clot within the last 3 months, or a CHA₂DS₂-VASc score of 5+ with prior stroke. For most people with atrial fibrillation, bridging isn’t needed. Always check your INR before stopping and after restarting.

Is bridging therapy safe?

It’s not inherently unsafe - but it’s risky for most people. The BRIDGE trial showed a 2.3% major bleeding rate with bridging versus 1.0% without. That’s more than double the risk. For patients not in the highest-risk group, the danger outweighs any benefit. Only use it if your doctor confirms you’re in the 10-15% who truly need it.

How long before surgery should I stop my blood thinner?

For warfarin: stop 5-6 days before. For LMWH: stop 24 hours before. For DOACs like apixaban or rivaroxaban: stop 24-48 hours before. For dabigatran: stop 48 hours before if you have kidney issues. Always confirm timing with your care team - it depends on your procedure and kidney function.

Can I switch from warfarin to a DOAC without bridging?

Yes. When switching from warfarin to a DOAC, stop warfarin and start the DOAC when your INR is below 2.0. No bridging is needed. For the reverse - DOAC to warfarin - start warfarin and a short-acting heparin at the same time, then stop the heparin once the INR is therapeutic. Always do this under medical supervision.

14 Comments

Chelsea Moore
Chelsea Moore
2 Dec 2025

So let me get this straight-doctors are still giving people 14 needle pokes a week… just because they’re scared of lawsuits??

Meanwhile, I’m on Eliquis, and I just skip my pill for 24 hours before my colonoscopy-no shots, no panic, no ‘bridging’ nonsense.

It’s not rocket science. It’s basic pharmacology. But somehow, medicine still thinks needles are better than pills??

What’s next? Bloodletting with leeches for high cholesterol?

I’m so tired of this. This isn’t medicine-it’s institutional inertia wrapped in a white coat.

And don’t even get me started on the cost-$500 for a week of shots?? That’s a month’s rent for some people!

Why do we still treat patients like they’re incapable of understanding simple science?

It’s not just dangerous-it’s disrespectful.

Stop bridging. Stop overtreating. Stop pretending fear is a valid medical rationale.

Someone needs to sue the AMA for malpractice by inertia.

John Morrow
John Morrow
4 Dec 2025

The BRIDGE trial’s findings, while statistically significant, must be contextualized within the broader pharmacokinetic and pharmacodynamic profiles of anticoagulant regimens.

It is not merely a binary choice between bridging and non-bridging; rather, one must consider thromboembolic risk stratification, procedural bleeding risk, renal clearance dynamics, and the temporal window of anticoagulant effect cessation.

While DOACs have indeed revolutionized outpatient anticoagulation, their rapid clearance-while advantageous in elective procedures-may pose challenges in emergent surgical scenarios where predictable reversal agents are not universally accessible.

Furthermore, the generalization of ‘no bridging needed’ across all DOAC users overlooks the heterogeneity of patient populations: those with extreme obesity, renal impairment, or hypercoagulable states may still benefit from bridging, even if they fall outside the traditional high-risk criteria.

The 75% adoption rate of DOACs reflects a paradigm shift, yes-but also a potential erosion of clinical nuance, where algorithmic decision-making replaces individualized risk-benefit analysis.

One must ask: are we optimizing for convenience, or for safety? And in the pursuit of convenience, have we inadvertently created a new class of iatrogenic risk?

Moreover, the economic argument-that LMWH is expensive-is misleading; when measured against hospitalization costs due to preventable thromboembolic events, the cost-benefit ratio may not be as clear-cut as suggested.

Thus, while the trend is sound, the dogma is dangerous.

Kristen Yates
Kristen Yates
5 Dec 2025

I’ve been on warfarin for 8 years. My doctor never bridged me for a knee scope. I just stopped it 5 days before. INR was fine. No problems.

It’s not complicated. Just ask your doctor why they’re doing it.

Saurabh Tiwari
Saurabh Tiwari
5 Dec 2025

bro honestly i just take my pill and forget about it

no needles no stress

doacs for life 🙌

Victoria Graci
Victoria Graci
6 Dec 2025

There’s something deeply ironic about how medicine, a field built on the pursuit of evidence, still clings to rituals born of fear rather than data.

We’ve moved from bloodletting to heparin injections, but the underlying mindset hasn’t changed: better to do something, even if it’s harmful, than to do nothing and risk blame.

It’s not just about anticoagulation-it’s about our collective inability to tolerate uncertainty.

We’ve turned medical decision-making into a performance of control: injections, lab tests, checklists, protocols-all designed to soothe the anxiety of the practitioner, not the patient.

The real breakthrough isn’t DOACs. It’s the quiet revolution of humility: admitting that sometimes, less is more.

That’s the hardest pill to swallow, isn’t it? Not the anticoagulant-but the realization that we don’t always need to fix what isn’t broken.

Maybe the future of medicine isn’t in new drugs, but in the courage to stop.

Chris Wallace
Chris Wallace
7 Dec 2025

I had a friend who got bridged for a dental extraction. She ended up with a hematoma the size of a grapefruit. Took weeks to go down.

She was on warfarin, but her CHA₂DS₂-VASc was 2. No history of clots. No mechanical valve.

The dentist said, ‘We’ve always done it this way.’

I’ve seen this too many times. It’s not incompetence-it’s institutional muscle memory.

Doctors aren’t evil. They’re just tired. And tired people follow the path of least resistance.

But that path is paved with unnecessary pain.

I wish more providers would pause before they prescribe. Just… pause.

Ask: ‘Is this helping, or just comforting me?’

william tao
william tao
9 Dec 2025

As a board-certified cardiologist with 22 years of clinical experience, I must respectfully dissent from the oversimplification presented herein.

The BRIDGE trial, while methodologically sound, excluded patients with mechanical mitral valves, which remain a high-risk cohort requiring bridging per ACC/AHA guidelines.

Furthermore, the generalization that DOACs eliminate the need for bridging ignores the reality of real-world adherence, renal dysfunction, and drug-drug interactions.

Moreover, the cost argument is disingenuous: LMWH is reimbursed under most insurance plans, whereas DOACs carry significant out-of-pocket costs for elderly patients on fixed incomes.

Thus, while the article contains elements of truth, it dangerously oversimplifies a nuanced clinical decision-making process.

Patients deserve more than TikTok medicine.

Sandi Allen
Sandi Allen
10 Dec 2025

Wait… so you’re telling me the pharmaceutical companies paid off the guidelines committee??

DOACs are expensive. LMWH is cheap. Why would they push DOACs if it wasn’t for profit??

And why is everyone suddenly ‘not needing bridging’? Coincidence? I think not.

They want you on a pill that you can’t reverse. That’s not safety-that’s control.

They don’t want you to survive a bleed. They want you to die quietly so they don’t have to pay.

Check the PAC funding. Check the CME sponsorships.

This isn’t medicine. It’s corporate manipulation dressed in white coats.

Don’t be fooled.

John Webber
John Webber
11 Dec 2025

my doc told me no bridge for my knee surgery and i was like wait really??

then i looked it up and yeah turns out i dont need it

so i just skipped my pill for a day and done

no needles no stress

why do people still do this??

its 2025

Shubham Pandey
Shubham Pandey
13 Dec 2025

DOACs = no bridge

Warfarin = only if high risk

Stop overthinking it

Elizabeth Farrell
Elizabeth Farrell
13 Dec 2025

I want to say thank you to whoever wrote this. I’ve been on warfarin for years, and I’ve had two surgeries where they wanted to bridge me.

I asked questions. I pushed back. I asked for the numbers. I asked what my actual risk was.

They didn’t bridge me either time. I had zero complications.

It felt scary, honestly. I was terrified I’d clot.

But trusting the data, trusting my doctors who listened, made all the difference.

If you’re reading this and you’re nervous about skipping a bridge-ask. Ask again. Ask until you feel safe.

You have the right to understand your care.

You don’t have to accept fear as a treatment plan.

You’re not alone in this.

Sheryl Lynn
Sheryl Lynn
13 Dec 2025

How delightfully pedestrian to reduce anticoagulation management to a binary of ‘need’ or ‘don’t need’.

The elegance of bridging therapy lies not in its ubiquity, but in its exquisite calibration-its capacity to interpolate between the chaotic kinetics of warfarin and the abrupt halts of DOACs.

One cannot reduce clinical wisdom to a bullet-pointed algorithm when the human body operates in gradients, not thresholds.

And while DOACs are indeed the darlings of the pharmaceutical zeitgeist, they are not panaceas-they are pharmacokinetic novelties, and their long-term effects in complex comorbidities remain… under-studied.

Let us not mistake popularity for profundity.

Paul Santos
Paul Santos
15 Dec 2025

Actually, I think this is a beautiful example of how evidence-based medicine is slowly dislodging tradition.

It’s not just about anticoagulants-it’s about the death of the ‘doctor knows best’ model.

We’re moving toward patient-centered, risk-stratified care.

And honestly? It’s about time.

DOACs are the future. Bridging is the relic.

And I’m here for it 🙌

Chelsea Moore
Chelsea Moore
15 Dec 2025

And yet, here we are-2025-and I just got an email from my doctor’s office: ‘We’re scheduling your LMWH injections for next week.’

I asked why. They said, ‘Because we always do.’

I’m on Eliquis. I had a colonoscopy last year. No bridge. No problem.

They didn’t even look at my chart.

So I called the surgeon. He said, ‘Oh, we just follow the template.’

So I emailed the hospital administrator.

They changed it.

Don’t let them treat you like a checkbox.

Be the pain in the ass.

It saves lives.

Write a comment

Your email address will be restricted to us